Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.18 Analyst target: $9.00 Upside: 662.71%
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.